Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Offering Veridex's CTC Test for Clinical Trials Research in China

NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

LabCorp's Beijing central laboratory is now the first clinical reference laboratory in the country to offer CTC testing and will offer the test to researchers conducting clinical trials.

The agreement follows regulatory approval in China last month for the test.

Drug developers use CTCs as a way of determining the efficacy of new drug treatments, and according to Veridex, a Johnson & Johnson company, CellSearch can identify as little as one CTC in a tube of blood.

Veridex acquired CellSearch when it bought Immunicon in 2008. The system is cleared by the US Food and Drug Administration for marketing in the US.

"As the number of clinical trials in China continues to rise, drug companies conducting trials there now have another compelling reason to incorporate CTCs into their protocols," Robert McCormack, head of Technology Innovation for Veridex, said in a statement. "Local testing will provide faster results for clinical trial investigators."

Terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.